Targeting cancer stem cells by curcumin and clinical applications

Cancer Letters

Volumn 346, Issue 2, 2014, Pages 197-205

  Li, Yanyan ^a   Zhang, Tao ^b  

^a MONTCLAIR STATE UNIVERSITY   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Cancer; Cancer stem cells; Clinical study; Curcumin

Indexed keywords

3,4 DIFLUOROBENZOCURCUMIN; ANTINEOPLASTIC AGENT; BETA CATENIN; BIOPTERIN; CAPECITABINE; CELECOXIB; CURCUMA EXTRACT; CURCUMIN; DASATINIB; DEMETHOXYCURCUMIN; DIDEMETHOXYCURCUMIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MICRORNA; NANOPARTICLE; NOTCH RECEPTOR; OXALIPLATIN; PACLITAXEL; PLANT EXTRACT; SONIC HEDGEHOG PROTEIN; THERACURMIN; UNCLASSIFIED DRUG; WNT PROTEIN;

ABERRANT CRYPT FOCUS; ADVANCED CANCER; APOPTOSIS; BILIARY TRACT CANCER; BLADDER CANCER; BOWEN DISEASE; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CELL RENEWAL; COLON CANCER; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED RELEASE FORMULATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG FORMULATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG TOLERABILITY; EPITHELIAL MESENCHYMAL TRANSITION; FAMILIAL COLON POLYPOSIS; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; INTESTINE METAPLASIA; LEUKOPLAKIA; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE MYELOMA; NANOENCAPSULATION; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROLACTINOMA; RECTUM CANCER; SHORT SURVEY; TOBACCO DEPENDENCE; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CARCINOMA IN SITU; ANIMAL; DRUG EFFECTS; NEOPLASMS; PATHOLOGY;

ANIMALIA; CURCUMA LONGA; ERINACEIDAE;

ANIMALS; ANTINEOPLASTIC AGENTS; CURCUMIN; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 84896119766     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.01.012     Document Type: Review

References (121)

1. Park C.H., Hahm E.R., Park S., Kim H.K., Yang C.H. The inhibitory mechanism of curcumin and its derivative against beta-catenin/Tcf signaling. FEBS Lett. 2005, 579:2965-2971.
2. Saha S., Adhikary A., Bhattacharyya P., Das T., Sa G. Death by design: where curcumin sensitizes drug-resistant tumours. Anticancer Res. 2012, 32:2567-2584.
3. Inoue K., Nomura C., Ito S., Nagatsu A., Hino T., Oka H. Purification of curcumin, demethoxycurcumin, and bisdemethoxycurcumin by high-speed countercurrent chromatography. J. Agric. Food Chem. 2008, 56:9328-9336.
4. Gupta S.C., Kismali G., Aggarwal B.B. Curcumin, a component of turmeric: from farm to pharmacy. BioFactors 2013, 39:2-13.
5. Aggarwal B.B., Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol. Sci. 2009, 30:85-94.
6. Satoskar R.R., Shah S.J., Shenoy S.G. Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation. Int. J. Clin. Pharmacol. Ther Toxicol. 1986, 24:651-654.
7. Mukhopadhyay A., Bueso-Ramos C., Chatterjee D., Pantazis P., Aggarwal B.B. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 2001, 20:7597-7609.
8. Shao Z.M., Shen Z.Z., Liu C.H., Sartippour M.R., Go V.L., Heber D., Nguyen M. Curcumin exerts multiple suppressive effects on human breast carcinoma cells. Int. J. Cancer 2002, 98:234-240.
9. Aggarwal B.B., Harikumar K.B. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J. Biochem. Cell Biol. 2009, 41:40-59.
10. Shehzad A., Wahid F., Lee Y.S. Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch. Pharm. 2010, 343:489-499.
11. Padhye S., Chavan D., Pandey S., Deshpande J., Swamy K.V., Sarkar F.H. Perspectives on chemopreventive and therapeutic potential of curcumin analogs in medicinal chemistry. Mini Rev. Med. Chem. 2010, 10:372-387.
12. Sarkar F.H., Li Y., Wang Z., Padhye S. Lesson learned from nature for the development of novel anti-cancer agents: implication of isoflavone, curcumin, and their synthetic analogs. Curr. Pharm. Des. 2010, 16:1801-1812.
13. Hossain D.M., Bhattacharyya S., Das T., Sa G. Curcumin: the multi-targeted therapy for cancer regression. Front. Biosci. 2012, 4:335-355.
14. Das T., Sa G., Saha B., Das K. Multifocal signal modulation therapy of cancer: ancient weapon, modern targets. Mol. Cell. Biochem. 2010, 336:85-95.
15. Aggarwal B.B., Sundaram C., Malani N., Ichikawa H. Curcumin: the Indian solid gold. Adv. Exp. Med. Biol. 2007, 595:1-75.
16. Anand P., Sundaram C., Jhurani S., Kunnumakkara A.B., Aggarwal B.B. Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett. 2008, 267:133-164.
17. Jagetia G.C., Aggarwal B.B. "Spicing up" of the immune system by curcumin. J. Clin. Immunol. 2007, 27:19-35.
18. Kuttan G., Kumar K.B., Guruvayoorappan C., Kuttan R. Antitumor, anti-invasion, and antimetastatic effects of curcumin. Adv. Exp. Med. Biol. 2007, 595:173-184.
19. Adams J.M., Strasser A. Is tumor growth sustained by rare cancer stem cells or dominant clones?. Cancer Res. 2008, 68:4018-4021.
20. Campbell L.L., Polyak K. Breast tumor heterogeneity: cancer stem cells or clonal evolution?. Cell Cycle 2007, 6:2332-2338.
21. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3:730-737.
22. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100:3983-3988.
23. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., Dirks P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63:5821-5828.
24. O'Brien C.A., Pollett A., Gallinger S., Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
25. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., Wicha M., Clarke M.F., Simeone D.M. Identification of pancreatic cancer stem cells. Cancer Res. 2007, 67:1030-1037.
26. Schatton T., Murphy G.F., Frank N.Y., Yamaura K., Waaga-Gasser A.M., Gasser M., Zhan Q., Jordan S., Duncan L.M., Weishaupt C., Fuhlbrigge R.C., Kupper T.S., Sayegh M.H., Frank M.H. Identification of cells initiating human melanomas. Nature 2008, 451:345-349.
27. Yang Z.F., Ho D.W., Ng M.N., Lau C.K., Yu W.C., Ngai P., Chu P.W., Lam C.T., Poon R.T., Fan S.T. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008, 13:153-166.
28. Liu S., Dontu G., Wicha M.S. Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res. 2005, 7:86-95.
29. Korkaya H., Paulson A., Charafe-Jauffret E., Ginestier C., Brown M., Dutcher J., Clouthier S.G., Wicha M.S. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol. 2009, 7:e1000121.
30. Zhou B.B., Zhang H., Damelin M., Geles K.G., Grindley J.C., Dirks P.B. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat. Rev. Drug. Discov. 2009, 8:806-823.
31. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
32. Shafee N., Smith C.R., Wei S., Kim Y., Mills G.B., Hortobagyi G.N., Stanbridge E.J., Lee E.Y. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res. 2008, 68:3243-3250.
33. Hambardzumyan D., Squatrito M., Holland E.C. Radiation resistance and stem-like cells in brain tumors. Cancer Cell 2006, 10:454-456.
34. Visvader J.E., Lindeman G.J. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 2012, 10:717-728.
35. Liu C., Li Y., Semenov M., Han C., Baeg G.H., Tan Y., Zhang Z., Lin X., He X. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002, 108:837-847.
36. Schweizer L., Varmus H. Wnt/Wingless signaling through beta-catenin requires the function of both LRP/Arrow and frizzled classes of receptors. BMC Cell Biol. 2003, 4:4.
37. He T.C., Sparks A.B., Rago C., Hermeking H., Zawel L., da Costa L.T., Morin P.J., Vogelstein B., Kinzler K.W. Identification of c-MYC as a target of the APC pathway. Science 1998, 281:1509-1512.
38. Tetsu O., McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999, 398:422-426.
39. Ryu M.J., Cho M., Song J.Y., Yun Y.S., Choi I.W., Kim D.E., Park B.S., Oh S. Natural derivatives of curcumin attenuate the Wnt/beta-catenin pathway through down-regulation of the transcriptional coactivator p300. Biochem. Biophys. Res. Commun. 2008, 377:1304-1308.
40. Jaiswal A.S., Marlow B.P., Gupta N., Narayan S. Beta-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene 2002, 21:8414-8427.
41. Kakarala M., Brenner D.E., Korkaya H., Cheng C., Tazi K., Ginestier C., Liu S., Dontu G., Wicha M.S. Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res Treat 2009.
42. Elamin M.H., Shinwari Z., Hendrayani S.F., Al-Hindi H., Al-Shail E., Khafaga Y., Al-Kofide A., Aboussekhra A. Curcumin inhibits the Sonic Hedgehog signaling pathway and triggers apoptosis in medulloblastoma cells. Mol. Carcinog. 2010, 49:302-314.
43. Prasad C.P., Rath G., Mathur S., Bhatnagar D., Ralhan R. Potent growth suppressive activity of curcumin in human breast cancer cells: modulation of Wnt/beta-catenin signaling. Chem. Biol. Interact. 2009, 181:263-271.
44. Yan C., Jamaluddin M.S., Aggarwal B., Myers J., Boyd D.D. Gene expression profiling identifies activating transcription factor 3 as a novel contributor to the proapoptotic effect of curcumin. Mol. Cancer Ther. 2005, 4:233-241.
45. Wang Z., Li Y., Banerjee S., Sarkar F.H. Emerging role of Notch in stem cells and cancer. Cancer Lett. 2009, 279:8-12.
46. Mumm J.S., Kopan R. Notch signaling: from the outside in. Dev. Biol. 2000, 228:151-165.
47. Borggrefe T., Oswald F. The Notch signaling pathway: transcriptional regulation at Notch target genes. Cell. Mol. Life Sci. 2009, 66:1631-1646.
48. Palomero T., Lim W.K., Odom D.T., Sulis M.L., Real P.J., Margolin A., Barnes K.C., O'Neil J., Neuberg D., Weng A.P., Aster J.C., Sigaux F., Soulier J., Look A.T., Young R.A., Califano A., Ferrando A.A. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc. Natl. Acad. Sci. USA 2006, 103:18261-18266.
49. Wang Z., Zhang Y., Banerjee S., Li Y., Sarkar F.H. Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer 2006, 106:2503-2513.
50. Liao S., Xia J., Chen Z., Zhang S., Ahmad A., Miele L., Sarkar F.H., Wang Z. Inhibitory effect of curcumin on oral carcinoma CAL-27 cells via suppression of Notch-1 and NF-kappaB signaling pathways. J. Cell. Biochem. 2011, 112:1055-1065.
51. Subramaniam D., Ponnurangam S., Ramamoorthy P., Standing D., Battafarano R.J., Anant S., Sharma P. Curcumin induces cell death in esophageal cancer cells through modulating Notch signaling. PLoS ONE 2012, 7:e30590.
52. Liu S., Dontu G., Mantle I.D., Patel S., Ahn N.S., Jackson K.W., Suri P., Wicha M.S. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 2006, 66:6063-6071.
53. Cohen M.M. The hedgehog signaling network. Am. J. Med. Genet. A 2003, 123A:5-28.
54. W.K. Syn, Y. Jung, A. Omenetti, M. Abdelmalek, C.D. Guy, L. Yang, J. Wang, R.P. Witek, C.M. Fearing, T.A. Pereira, V. Teaberry, S.S. Choi, J. Conde-Vancells, G.F. Karaca, A.M. Diehl, Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease, Gastroenterology, 137 (2009) 1478-1488 e1478.
55. Lim K.J., Bisht S., Bar E.E., Maitra A., Eberhart C.G. A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors. Cancer Biol. Ther. 2011, 11:464-473.
56. Slusarz A., Shenouda N.S., Sakla M.S., Drenkhahn S.K., Narula A.S., MacDonald R.S., Besch-Williford C.L., Lubahn D.B. Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer. Cancer Res. 2010, 70:3382-3390.
57. Filipowicz W., Bhattacharyya S.N., Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?. Nat. Rev. Genet. 2008, 9:102-114.
58. Neelakandan K., Babu P., Nair S. Emerging roles for modulation of microRNA signatures in cancer chemoprevention. Curr. Cancer Drug Targets 2012, 12:716-740.
59. Li Y., Kong D., Wang Z., Sarkar F.H. Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research. Pharm. Res. 2010, 27:1027-1041.
60. Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., Sweet-Cordero A., Ebert B.L., Mak R.H., Ferrando A.A., Downing J.R., Jacks T., Horvitz H.R., Golub T.R. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
61. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6:857-866.
62. Tiscornia G., Izpisua Belmonte J.C. MicroRNAs in embryonic stem cell function and fate. Genes Dev 2010, 24:2732-2741.
63. Mallick B., Chakrabarti J., Ghosh Z. MicroRNA reins in embryonic and cancer stem cells. RNA Biol. 2011, 8:415-426.
64. Bao B., Ahmad A., Li Y., Azmi A.S., Ali S., Banerjee S., Kong D., Sarkar F.H. Targeting CSCs within the tumor microenvironment for cancer therapy: a potential role of mesenchymal stem cells. Expert Opin. Ther. Targets 2012, 16:1041-1054.
65. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., Brooks M., Reinhard F., Zhang C.C., Shipitsin M., Campbell L.L., Polyak K., Brisken C., Yang J., Weinberg R.A. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
66. Merchant A.A., Matsui W. Targeting Hedgehog - a cancer stem cell pathway. Clin. Cancer Res. 2010, 16:3130-3140.
67. Bao B., Wang Z., Ali S., Kong D., Li Y., Ahmad A., Banerjee S., Azmi A.S., Miele L., Sarkar F.H. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett. 2011, 307:26-36.
68. Ouyang G., Wang Z., Fang X., Liu J., Yang C.J. Molecular signaling of the epithelial to mesenchymal transition in generating and maintaining cancer stem cells. Cell. Mol. Life Sci. 2010, 67:2605-2618.
69. Iliopoulos D., Lindahl-Allen M., Polytarchou C., Hirsch H.A., Tsichlis P.N., Struhl K. Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol. Cell 2010, 39:761-772.
70. Leal J.A., Lleonart M.E. MicroRNAs and cancer stem cells: therapeutic approaches and future perspectives. Cancer Lett. 2012.
71. Shimono Y., Zabala M., Cho R.W., Lobo N., Dalerba P., Qian D., Diehn M., Liu H., Panula S.P., Chiao E., Dirbas F.M., Somlo G., Pera R.A., Lao K., Clarke M.F. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009, 138:592-603.
72. Tili E., Michaille J.J. Resveratrol MicroRNAs, inflammation, and cancer. J. Nucleic Acids 2011, 2011:102431.
73. Sun M., Estrov Z., Ji Y., Coombes K.R., Harris D.H., Kurzrock R. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol. Cancer Ther. 2008, 7:464-473.
74. Zhang J., Du Y., Wu C., Ren X., Ti X., Shi J., Zhao F., Yin H. Curcumin promotes apoptosis in human lung adenocarcinoma cells through miR-186* signaling pathway. Oncol. Rep. 2010, 24:1217-1223.
75. Zhang J., Zhang T., Ti X., Shi J., Wu C., Ren X., Yin H. Curcumin promotes apoptosis in A549/DDP multidrug-resistant human lung adenocarcinoma cells through an miRNA signaling pathway. Biochem. Biophys. Res. Commun. 2010, 399:1-6.
76. Li Y., VandenBoom T.G., Kong D., Wang Z., Ali S., Philip P.A., Sarkar F.H. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 2009, 69:6704-6712.
77. Ali S., Ahmad A., Banerjee S., Padhye S., Dominiak K., Schaffert J.M., Wang Z., Philip P.A., Sarkar F.H. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res. 2010, 70:3606-3617.
78. Padhye S., Banerjee S., Chavan D., Pandye S., Swamy K.V., Ali S., Li J., Dou Q.P., Sarkar F.H. Fluorocurcumins as cyclooxygenase-2 inhibitor: molecular docking, pharmacokinetics and tissue distribution in mice. Pharm. Res. 2009, 26:2438-2445.
79. Padhye S., Yang H., Jamadar A., Cui Q.C., Chavan D., Dominiak K., McKinney J., Banerjee S., Dou Q.P., Sarkar F.H. New difluoro Knoevenagel condensates of curcumin, their Schiff bases and copper complexes as proteasome inhibitors and apoptosis inducers in cancer cells. Pharm. Res. 2009, 26:1874-1880.
80. Bao B., Ali S., Banerjee S., Wang Z., Logna F., Azmi A.S., Kong D., Ahmad A., Li Y., Padhye S., Sarkar F.H. Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res. 2012, 72:335-345.
81. Bao B., Ali S., Kong D., Sarkar S.H., Wang Z., Banerjee S., Aboukameel A., Padhye S., Philip P.A., Sarkar F.H. Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS ONE 2011, 6:e17850.
82. Bao B., Ahmad A., Kong D., Ali S., Azmi A.S., Li Y., Banerjee S., Padhye S., Sarkar F.H. Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF. PLoS ONE 2012, 7:e43726.
83. Dontu G., Abdallah W.M., Foley J.M., Jackson K.W., Clarke M.F., Kawamura M.J., Wicha M.S. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003, 17:1253-1270.
84. Charafe-Jauffret E., Monville F., Ginestier C., Dontu G., Birnbaum D., Wicha M.S. Cancer stem cells in breast: current opinion and future challenges. Pathobiology 2008, 75:75-84.
85. Marshall G.P., Reynolds B.A., Laywell E.D. Using the neurosphere assay to quantify neural stem cells in vivo. Curr. Pharm. Biotechnol. 2007, 8:141-145.
86. Hemmati H.D., Nakano I., Lazareff J.A., Masterman-Smith M., Geschwind D.H., Bronner-Fraser M., Kornblum H.I. Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl. Acad. Sci. USA 2003, 100:15178-15183.
87. Ginestier C., Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., Jacquemier J., Viens P., Kleer C.G., Liu S., Schott A., Hayes D., Birnbaum D., Wicha M.S., Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
88. Hadnagy A., Gaboury L., Beaulieu R., Balicki D. SP analysis may be used to identify cancer stem cell populations. Exp. Cell Res. 2006, 312:3701-3710.
89. Hirschmann-Jax C., Foster A.E., Wulf G.G., Nuchtern J.G., Jax T.W., Gobel U., Goodell M.A., Brenner M.K. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc. Natl. Acad. Sci. USA 2004, 101:14228-14233.
90. Fong D., Yeh A., Naftalovich R., Choi T.H., Chan M.M. Curcumin inhibits the side population (SP) phenotype of the rat C6 glioma cell line: towards targeting of cancer stem cells with phytochemicals. Cancer Lett. 2010, 293:65-72.
91. Zhuang W., Long L., Zheng B., Ji W., Yang N., Zhang Q., Liang Z. Curcumin promotes differentiation of glioma-initiating cells by inducing autophagy. Cancer Sci. 2012, 103:684-690.
92. Almanaa T.N., Geusz M.E., Jamasbi R.J. Effects of curcumin on stem-like cells in human esophageal squamous carcinoma cell lines. BMC Complement Altern Med 2012, 12:195.
93. Yu Y., Kanwar S.S., Patel B.B., Nautiyal J., Sarkar F.H., Majumdar A.P. Elimination of colon cancer stem-like cells by the combination of curcumin and FOLFOX. Translational Oncol. 2009, 2:321-328.
94. Nautiyal J., Kanwar S.S., Yu Y., Majumdar A.P. Combination of dasatinib and curcumin eliminates chemo-resistant colon cancer cells. J. Mol. Signal. 2011, 6:7.
95. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J. Cancer statistics. CA Cancer J. Clin. 2007, 57(2007):43-66.
96. Patel B.B., Sengupta R., Qazi S., Vachhani H., Yu Y., Rishi A.K., Majumdar A.P. Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. Int. J. Cancer 2008, 122:267-273.
97. Dalerba P., Dylla S.J., Park I.K., Liu R., Wang X., Cho R.W., Hoey T., Gurney A., Huang E.H., Simeone D.M., Shelton A.A., Parmiani G., Castelli C., Clarke M.F. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. USA 2007, 104:10158-10163.
98. Hossain M., Banik N.L., Ray S.K. Synergistic anti-cancer mechanisms of curcumin and paclitaxel for growth inhibition of human brain tumor stem cells and LN18 and U138MG cells. Neurochem. Int. 2012, 61:1102-1113.
99. Rasper M., Schafer A., Piontek G., Teufel J., Brockhoff G., Ringel F., Heindl S., Zimmer C., Schlegel J. Aldehyde dehydrogenase 1 positive glioblastoma cells show brain tumor stem cell capacity. Neuro Oncol. 2010, 12:1024-1033.
100. Dhillon N., Aggarwal B.B., Newman R.A., Wolff R.A., Kunnumakkara A.B., Abbruzzese J.L., Ng C.S., Badmaev V., Kurzrock R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res. 2008, 14:4491-4499.
101. Anand P., Kunnumakkara A.B., Newman R.A., Aggarwal B.B. Bioavailability of curcumin: problems and promises. Mol. Pharm. 2007, 4:807-818.
102. Wahlstrom B., Blennow G. A study on the fate of curcumin in the rat. Acta pharmacologica et toxicologica 1978, 43:86-92.
103. Kanwar S.S., Yu Y., Nautiyal J., Patel B.B., Padhye S., Sarkar F.H., Majumdar A.P. Difluorinated-curcumin (CDF): a novel curcumin analog is a potent inhibitor of colon cancer stem-like cells. Pharm. Res. 2011, 28:827-838.
104. Hutzen B., Friedman L., Sobo M., Lin L., Cen L., De Angelis S., Yamakoshi H., Shibata H., Iwabuchi Y., Lin J. Curcumin analogue GO-Y030 inhibits STAT3 activity and cell growth in breast and pancreatic carcinomas. Int. J. Oncol. 2009, 35:867-872.
105. Lin L., Liu Y., Li H., Li P.K., Fuchs J., Shibata H., Iwabuchi Y., Lin J. Targeting colon cancer stem cells using a new curcumin analogue, GO-Y030. Br. J. Cancer 2011, 105:212-220.
106. Wang K., Zhang T., Liu L., Wang X., Wu P., Chen Z., Ni C., Zhang J., Hu F., Huang J. Novel micelle formulation of curcumin for enhancing antitumor activity and inhibiting colorectal cancer stem cells. Int. J. Nanomed. 2012, 7:4487-4497.
107. Kanai M., Otsuka Y., Otsuka K., Sato M., Nishimura T., Mori Y., Kawaguchi M., Hatano E., Kodama Y., Matsumoto S., Murakami Y., Imaizumi A., Chiba T., Nishihira J., Shibata H. A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients. Cancer Chemother. Pharmacol. 2013, 71:1521-1530.
108. Kanai M., Yoshimura K., Asada M., Imaizumi A., Suzuki C., Matsumoto S., Nishimura T., Mori Y., Masui T., Kawaguchi Y., Yanagihara K., Yazumi S., Chiba T., Guha S., Aggarwal B.B. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother. Pharmacol. 2011, 68:157-164.
109. Bayet-Robert M., Kwiatkowski F., Leheurteur M., Gachon F., Planchat E., Abrial C., Mouret-Reynier M.A., Durando X., Barthomeuf C., Chollet P. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol. Ther. 2010, 9:8-14.
110. Sharma R.A., Euden S.A., Platton S.L., Cooke D.N., Shafayat A., Hewitt H.R., Marczylo T.H., Morgan B., Hemingway D., Plummer S.M., Pirmohamed M., Gescher A.J., Steward W.P. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin. Cancer Res. 2004, 10:6847-6854.
111. Sharma R.A., McLelland H.R., Hill K.A., Ireson C.R., Euden S.A., Manson M.M., Pirmohamed M., Marnett L.J., Gescher A.J., Steward W.P. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin. Cancer Res. 2001, 7:1894-1900.
112. Cheng A.L., Hsu C.H., Lin J.K., Hsu M.M., Ho Y.F., Shen T.S., Ko J.Y., Lin J.T., Lin B.R., Ming-Shiang W., Yu H.S., Jee S.H., Chen G.S., Chen T.M., Chen C.A., Lai M.K., Pu Y.S., Pan M.H., Wang Y.J., Tsai C.C., Hsieh C.Y. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001, 21:2895-2900.
113. Asher G.N., Spelman K. Clinical utility of curcumin extract. Altern. Ther. Health Med. 2013, 19:20-22.
114. Mancuso A., Calabro F., Sternberg C.N. Current therapies and advances in the treatment of pancreatic cancer. Crit. Rev. Oncol./Hematol. 2006, 58:231-241.
115. M.J. Moore, D. Goldstein, J. Hamm, A. Figer, J.R. Hecht, S. Gallinger, H.J. Au, P. Murawa, D. Walde, R.A. Wolff, D. Campos, R. Lim, K. Ding, G. Clark, T. Voskoglou-Nomikos, M. Ptasynski, W. Parulekar, G. National Cancer Institute of Canada Clinical Trials, Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group, J Clin Oncol 25 (2007) 1960-1966.
116. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Cripps M.C., Portenoy R.K., Storniolo A.M., Tarassoff P., Nelson R., Dorr F.A., Stephens C.D., Von Hoff D.D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15:2403-2413.
117. Sasaki H., Sunagawa Y., Takahashi K., Imaizumi A., Fukuda H., Hashimoto T., Wada H., Katanasaka Y., Kakeya H., Fujita M., Hasegawa K., Morimoto T. Innovative preparation of curcumin for improved oral bioavailability. Biol. Pharm. Bull. 2011, 34:660-665.
118. Kanai M., Imaizumi A., Otsuka Y., Sasaki H., Hashiguchi M., Tsujiko K., Matsumoto S., Ishiguro H., Chiba T. Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers. Cancer Chemother. Pharmacol. 2012, 69:65-70.
119. Gupta S.C., Patchva S., Aggarwal B.B. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J 2013, 15:195-218.
120. Gota V.S., Maru G.B., Soni T.G., Gandhi T.R., Kochar N., Agarwal M.G. Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. J. Agric. Food Chem. 2010, 58:2095-2099.
121. Cuomo J., Appendino G., Dern A.S., Schneider E., McKinnon T.P., Brown M.J., Togni S., Dixon B.M. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J. Nat. Prod. 2011, 74:664-669.